Benjamin Brennecke, Thais Gazzi, Kenneth Atz, Jürgen Fingerle, Pascal Kuner, Torsten Schindler, Guy de Weck, Marc Nazaré, Uwe Grether
{"title":"大麻素受体2型配体:2010年以来授权专利分析。","authors":"Benjamin Brennecke, Thais Gazzi, Kenneth Atz, Jürgen Fingerle, Pascal Kuner, Torsten Schindler, Guy de Weck, Marc Nazaré, Uwe Grether","doi":"10.4155/ppa-2021-0002","DOIUrl":null,"url":null,"abstract":"<p><p>The G-protein-coupled cannabinoid receptor type 2 (CB<sub>2</sub>R) is a key element of the endocannabinoid (EC) system. EC/CB<sub>2</sub>R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB<sub>2</sub>R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB<sub>2</sub>R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB<sub>2</sub>R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation<sup>®</sup>.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 3","pages":"111-163"},"PeriodicalIF":1.8000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.\",\"authors\":\"Benjamin Brennecke, Thais Gazzi, Kenneth Atz, Jürgen Fingerle, Pascal Kuner, Torsten Schindler, Guy de Weck, Marc Nazaré, Uwe Grether\",\"doi\":\"10.4155/ppa-2021-0002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The G-protein-coupled cannabinoid receptor type 2 (CB<sub>2</sub>R) is a key element of the endocannabinoid (EC) system. EC/CB<sub>2</sub>R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB<sub>2</sub>R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB<sub>2</sub>R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB<sub>2</sub>R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation<sup>®</sup>.</p>\",\"PeriodicalId\":20011,\"journal\":{\"name\":\"Pharmaceutical patent analyst\",\"volume\":\"10 3\",\"pages\":\"111-163\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical patent analyst\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4155/ppa-2021-0002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/6/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical patent analyst","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/ppa-2021-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.
The G-protein-coupled cannabinoid receptor type 2 (CB2R) is a key element of the endocannabinoid (EC) system. EC/CB2R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB2R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB2R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB2R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation®.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
